Results
1 -
10 of
18Thrombin Receptor Modulators: Medicinal Chemistry, Biological Evaluation, and Clinical Application, Thrombin PAR Antagonists, Platelets in Thrombotic and Non-Thrombotic Disorders PAR-1 Inhibitors: A Novel Class of Antiplatelet Agents for the Treatment of Patients with Atherothrombosis, Antiplatelet Agents PAR-1 antagonists: current state of evidence, Journal of Thrombosis and Thrombolysis Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program, Journal of Thrombosis and Thrombolysis Oral Antiplatelet Therapy for Acute and Chronic Management of NSTE ACS: Residual Ischemic Risk and Opportunities for Improvement, Cardiovascular Drugs and Therapy Platelet Function and Inhibition in Ischemic Heart Disease, Current Cardiology Reports Beyond Aspirin and Clopidogrel: Is There a Need for Additional Antiplatelet Therapy in ACS?, Current Cardiology Reports Promises of PAR-1 Inhibition in Acute Coronary Syndrome, Current Cardiology Reports Novel Anti-platelet Agents: Focus on Thrombin Receptor Antagonists, Journal of Cardiovascular Translational Research